catechin has been researched along with AL Amyloidosis in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 1 (50.00) | 2.80 |
Authors | Studies |
---|---|
Abe, Y; Caaveiro, JMM; Matsunaga, E; Takahashi, D; Ueda, T; Yamashita, T | 1 |
Goto, M; Hotta, M; Kobayashi, M; Meshitsuka, S; Nojima, M; Sagesaka, YM; Shingaki, S; Suzuki, K; Ukawa, Y; Wada, Y | 1 |
1 trial(s) available for catechin and AL Amyloidosis
Article | Year |
---|---|
Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis.
Topics: Adult; Aged; Aged, 80 and over; Amyloidosis; Antioxidants; Catechin; Female; Humans; Immunoglobulin Light-chain Amyloidosis; Male; Middle Aged; Oxidative Stress; Reactive Oxygen Species; Tea; Treatment Outcome | 2017 |
1 other study(ies) available for catechin and AL Amyloidosis
Article | Year |
---|---|
Compound screening identified gossypetin and isoquercitrin as novel inhibitors for amyloid fibril formations of Vλ6 proteins associated with AL amyloidosis.
Topics: Amyloid; Antioxidants; Catechin; Dose-Response Relationship, Drug; Flavonoids; Humans; Immunoglobulin lambda-Chains; Immunoglobulin Light-chain Amyloidosis; Kinetics; Magnetic Resonance Spectroscopy; Molecular Structure; Mutation; Protein Binding; Protein Stability; Quercetin; Time Factors | 2022 |